E2F3 and neuroblastoma: On the contrary, pediatric neuroblastoma patients with age at diagnosis ≥ 18 months and with higher E2F3 expression levels had the worst clinical event free survival and overall survival than other sub-groups (Fig. 6b and supplementary Fig. 3b).